Purine nucleotide metabolism: specific aspects in chronic lymphocytic leukemia lymphocytes  by Carlucci, F et al.
 .Biochimica et Biophysica Acta 1360 1997 203–210
Purine nucleotide metabolism: specific aspects in chronic lymphocytic
leukemia lymphocytes
F. Carlucci, F. Rosi, C. Di Pietro, E. Marinello ), M. Pizzichini, A. Tabucchi
Istituto di Biochimica e di Enzimologia, Uni˝ersita degli Studi di Siena, Pian dei Mantellini 44, 53100 Siena, Italy`
Received 21 October 1996; accepted 5 December 1996
Abstract
The metabolism of purine nucleotides was studied in human peripheral blood lymphocytes from healthy subjects and
patients with B-cell chronic lymphocytic leukemia. Nucleotide content was determined by HPLC. The rate of de novo
synthesis of purine nucleotides was measured kinetically by following the incorporation of 14C-formate into the nucleotides
of a lymphocyte suspension. The patterns of the main enzymes involved in purine nucleotide metabolism those of the
.salvage pathway and catabolism were estimated by a radiochemical method. Although the data expressed in relation to
cells and protein showed some discrepancies, several common differences were evident in both cases. The main differences
were an increase in NAD and IMP, a sharp decrease in 5X-nucleotidase activities and in total guanylate content and
synthesis, and an increase in the ArG ratio in lymphocytes of patients with respect to controls. The changes in these
parameters in CLL indicate an imbalance in purine metabolism and may play a specific role in the biology of the leukemia
cell. They are also potential biochemical markers of lymphoid malignancies and may be useful in chemotherapic
applications. q1997 Elsevier Science B.V. All rights reserved.
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Abbreviations: A, total adenine nucleotides; ADA, adenosine
deaminase; AMP-D, AMP deaminase; APRT, adenine phosphori-
bosyltransferase; B-CLL, B-cell chronic lymphocytic leukemia;
EC, energy charge; FACS, fluorescence activated cell sorter; G,
total guanine nucleotides; HGPRT, hypoxanthine-guanine phos-
phoribosyltransferase; HPLC, high performance liquid chro-
matography; 5X-N, 5X-nucleotidase; NDP, nucleoside diphosphate;
NMP, nucleoside monophosphate; NTP, nucleoside triphos-
phates; PBS, phosphate buffered saline; PNP, purine nucleoside
phosphorylase; PRPP, 5X-phosphoribosyl 1-pyrophosphate;
w3 x w3 xH dThd, H deoxythymidine.
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1. Introduction
The study of purine nucleotide metabolism is very
important for a correct understanding of the life of
the cell. Nucleotides are direct precursors of RNA
and DNA. They are involved in most energy-requir-
ing metabolic reactions and act as coenzymes.
Purine nucleotide metabolism is based on three
fundamental pathways: de no˝o synthesis, the sal-
˝age pathway and the catabolic pathway.
 .Such metabolism can be studied by: 1 evaluation
 .of intracellular content; 2 the kinetics of incorpora-
w xtion of labelled precursors 1 , an index of the overall
 .rate of de novo synthesis; 3 evaluation of the
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enzyme activities involved in nucleotide catabolism:
AMP-deaminase, 5X-nucleotidase, adenosine deami-
nase and purine nucleoside phosphorylase.
Among the catabolic enzymes, the isoenzymes of
X  .5 -nucleotidase EC 3.1.3.5 are the rate limiting step
of overall purine nucleotide catabolism: they catalyze
the dephosphorylation of nucleoside monophosphates
to the corresponding nucleosides. Three different iso-
forms of 5X-nucleotidase have been identified in hu-
man lymphocytes. One form is located at the surface
of the cells, acts preferentially on AMP and is called
X w x Xecto-5 -nucleotidase 2,3 . Two isoforms of 5 -nucleo-
tidase have been described in the cytosol: e-Ns,
which catalyzes the dephosphorylation of AMP to
X w xadenosine and is derived from ecto-5 N 2 , and
w xc-N-II, which degrades IMP to inosine 4 .
Although study of purine nucleotide metabolism in
leukemia patients is not limited by the availability of
cells, our knowlegde in this field is still incomplete.
Literature reports the activity of some specific en-
 Xzymes adenosine deaminase, 5 -nucleotidase and
. w xpurine nucleoside phosphorylase 5–7 , while De
Korte et al. analyze the nucleotide profiles of normal
human blood cells, with specific reference to pyrimi-
dine nucleotides and related enzymes in human lym-
w xphoblastic and myeloid leukemia 8–11 .
Some papers have attempted to study the complete
purine metabolic pathways in white blood cells.
w xScholar and Calabresi 12 measured the activities of
19 purine and pyrimidine enzyme systems in extracts
of normal and leukemic lymphocytes. Henderson et
w xal. 13 worked with intact mixed leukocytes and
studied all the radioactive products formed after incu-
bation with radioactive adenine, hypoxanthine and
guanine.
In the present study we tried to obtain a complete
overview of purine nucleotide metabolism in the
lymphocytes of B-cell chronic lymphocytic leukemia
patients, analyzing its different aspects. First we mea-
sured lymphocytic levels of the principal nucleotides
NAD, AMP, IMP, GMP, ADP, GDP, ATP and
.GTP by HPLC. We calculated the parameters which
can be deduced from their concentrations: EC-AMP,
EC-GMP, ATPrADP and GTPrGDP, which repre-
sent the energy and viability of the cells, the total
 .adenylatertotal guanylate ratio ArG ratio which is
inversely related to cell proliferation and to nucleic
w xacid production 8,14–16 . We then studied de novo
synthesis by following the incorporation of a labelled
precursor, 14C-formate, into IMP, total adenylates and
total guanylates. Finally, we investigated the enzymes
of the salvage pathway and the catabolic enzymes,
especially the isoenzymes of 5X-nucleotidase.
2. Materials and methods
2.1. Chemicals
The nucleotides used as chromatographic standards
were obtained from Sigma Chemical Corp. St. Louis,
.MO, USA . All radiochemicals were obtained from
 .Amersham International Amersham, U.K. ; Lym-
phoprep was from Nycomed Pharma AS. Oslo, Nor-
way. All other chemicals were of analytical grade
 .from Merck Darmstadt, Germany . All HPLC sol-
vents were filtered through 0.45 mm membrane fil-
 .ters Sartorius, GmbH, Gottingen, Germany prior to¨
use.
2.2. Instrumentation
For HPLC analysis we used a Beckman chromato-
graph equipped with two mod. 110 B pumps and a
mod. 166 UV detector set at 254 nm. Identification of
nucleotides, nucleosides and nucleobases, and quan-
tification were carried out as previously described
w x1,8,17 .
For the evaluation of purine nucleotide content and
for the kinetic study, the chromatograph was equipped
with a Whatman Partisil 10 SAX anion-exchange
 .column 5 mm 4.6=250 mm , while for the enzyme
determinations we used a Supelcosil LC-18 column 5
 .mm 4.6 =250 mm .
In the radiochemical determinations, the peaks cor-
responding to the various compounds were collected
directly in scintillation vials and their radioactivity
was determined in a liquid scintillation counter.
2.3. Patients
 .25 healthy subjects age 48–65 years and 25
 .leukemia patients 52–78 years were studied. The
patients had a mean history of B-cell chronic lym-
phocytic leukemia of 2.5 years "0.5. Diagnosis was
based on peripheral blood lymphocyte count
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 3.22 000–425 000rmm , bone marrow parameters
and lymphocyte type determined by cytofluorimetry
and immunocytochemistry. As far as could be deter-
mined, at the moment of the blood withdrawn, the
patients underwent no chemotherapy for the past 2
mth.
2.4. Preparation of total peripheral blood lympho-
( )cytes PBL
All blood samples were drawn in the morning 8
.a.m. after overnight fasting; 80 ml of blood from
normal subjects was usually sufficient for all determi-
nations. In the leukemia patients, volumes propor-
tional to the counts were used. The lymphocytes were
w xisolated from whole blood by density flotation 18 .
To eliminate any contaminating platelets, the lym-
phocyte sediment was suspended in PBS, stirring
carefully with a glass rod: no contamination was
evident by FACS examination. Lymphocytes were
finally suspended in 290 mM sucrose containing 10
 .mM Tris buffer pH 7 , at a final concentration of
140 000rml. The cells were counted in a Delcon cell
counter. Cell viability was checked by the Trypan
blue exclusion test. The number of dead cells was not
significant.
2.5. Purine nucleotide determination
20=106 cells were used for purine nucleotide
analysis. The suspensions of PBL were spun down at
1000=g and the supernatants removed. After three
washings with PBS, the lymphocyte pellets were
w xdeproteinized by the procedure of De Korte et al. 8 .
All the details of the preparation of perchloric ex-
tracts and the criteria of determination of nucleotides
by HPLC have been reported in previous papers
w x1,8,17 .
2.6. Kinetic rate of de no˝o synthesis of IMP, adeny-
lates and guanylates
The incorporation of 14C-formate into total adenine
 .nucleotides AsAMPqADPqATP , total guanine
 .nucleotides GsGMPqGDPqGTP and IMP is
an index of de novo synthesis of purine nucleotides.
We evaluated the kinetic rate of de novo synthesis in
the lymphocytes of healthy subjects and B-CLL pa-
tients, according to the indications of Gordon et al.
w x19 . After a pre-incubation period of 30 min, 2 mM
14  .glutamine and 0.5 mM C-formate 25 mCirmmol
were added to the incubation buffer and the cells
incubated for 15, 30, 60, 90 and 150 min. The
lymphocytes were incubated at a density of 6=106
cellsrml in an atmosphere of 5% CO at 378C. At2
the above times, 6=106 cells were taken and washed
twice with 2 ml ice-cold PBS, then 100 ml ice-cold
0.4 N HClO was added to the cell pellet. The4
acid-soluble supernatant was neutralized and the nu-
cleotides were evaluated as previously reported
w x1,8,17 . The radioactivity incorporated into the vari-
ous compounds was determined as reported in Sec-
tion 2.
2.7. Determination of enzymes
Lymphocyte extracts for all enzyme determina-
tions were prepared by ultrasound treatment 3 cycles
.of 20 s with 40 s intervals in the between , and lysis
was checked by microscope. Extracts were spun down
at 300=g and the pellets were discarded. The super-
 . natant 1 ml was treated with Norit A 150 ml of
.50% Norit A in H O , to eliminate endogenous2
nucleotides which can interfere with enzyme activi-
ties.
For determination of all enzyme activities we
adopted the radiochemical method coupled with
HPLC. We incubated radioactive substrates with lysed
extracts, and followed either the disappearance of the
substrates or the formation of labelled products: the
metabolites were separated by HPLC and identified,
then estimated by determining the radioactivity of the
peaks. In the case of ecto-5Xnucleotidase, incubation
mixtures contained whole cells instead of lysed ex-
tracts.
Some of the methods and experimental conditions
whave already been described in the literature 12,20–
x22 ; they were improved in our laboratory or adapted
for the determination of enzymes in lymphoid cells.
Suitable controls were run to ascertain that activity
was linear with time and proportional to cells and
protein concentration in all cases. Deproteinization of
incubation mixtures was carried out with a final 0.21
N concentration of HClO and neutralization with a4
final 0.22 N concentration of KOH. A 20 ml sample
was injected for HPLC analysis by overloading the
injection loop with 50 ml.
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Table 1
Nucleotide content of lymphocytes of healthy subjects and B-CLL patients
 .  .Nucleotides Healthy ns12 B-CLL ns12 % Variation Healthy B-CLL % Variation
6 6 6 .  .  .   pmolr10 cells pmolr10 cells pmolr10 cells nmolrmg nmolrmg nmolrmg
. . .protein protein protein
) )AMP 89"23 113"42 q27 2.43"0.63 5.32"1.98 q119
)ADP 648"166 374"63 y42 17.71"7.82 17.62"2.96 r
)ATP 1128"411 509"126 y55 30.82"11.23 23.98"5.93 y22
GMP 67"10 44"14 y34 1.83"0.27 2.07"0.66 q13
) )GDP 162"36 67"11 y61 4.42"0.98 3.16"0.52 y28
) )GTP 345"73 104"22 y70 9.42"0.25 4.90"1.04 y48
) )NAD 347"109 523"167 q50 9.48"2.98 24.64"7.87 q160
) )IMP 106"63 273"100 q157 2.89"1.72 12.86"4.71 q345
)Total adenylates 1865 996 y46 50.97 46.93 y8
) )Total guanylates 574 215 y62 15.68 10.13 y35
Total nucleotides 2892 2007 y31 79.04 94.58 q20
6  .The values are expressed in pmolr10 cells and pmolrmg protein mean"SE . Total adenylates, total guanylates and total nucleotides
were calculated from the mean values.
ns number of cases.
) P-0.05 with respect to healthy subjects.
2.7.1. Enzymes of the sal˝age pathway
Adenine phosphoribosyltransferase EC 2.4.2.7 —
.APRT activity was measured as described by Scholar
w xand Calabresi 12 , by following the formation of
14 w xC-AMP 23 . Hypoxanthine-guanine phosphoribo-
 .syltransferase EC 2.4.2.8 — HGPRT activity was
assayed by following the formation of 14C-IMP from
14 w xC-hypoxanthine, according to Rylance et al. 24 ,
with some modifications for the chromatographic
separation.
2.7.2. Enzymes of nucleotide catabolism
 .AMP deaminase EC 3.5.4.6, AMP-D activity
was measured by evaluating the formation of 14C-
w xIMP, as already reported 25 . For the following
enzymes, HPLC elution of substrates and products
w xwas performed according to Harmsen et al. 26 . Ecto
X  X .5 -nucleotidase EC 3.1.3.5, 5 -N activity was evalu-
w xated according to Bontemps et al. 20 , by following
the disappearance of 14C-AMP. The incubation mix-
X ture contained whole cells. Endo 5 -nucleotidase e-
.Ns activity was evaluated by an identical procedure,
and with an incubation mixture as 5X-N and extract of
 .lysed lymphocytes. IMP-ase ATP-activated c-N-II
w xactivity was evaluated according to Isaza 4 , follow-
ing the disappearance of 14C-IMP. Adenosine deami-
 .nase EC 3.5.4.4 - ADA activity was followed
through the formation of 14C-inosine from 14C-
adenosine in the incubation mixture as reported by
w x Daddona 21 . Purine nucleoside phosphorylase EC
.2.4.2.1 - PNP activity was assayed through the
formation of 14C-hypoxanthine from 14C-inosine, ac-
w xcording to Peters et al. 27 .
Table 2
Principal significant ratios of various nucleotides in lymphocytes
of healthy subjects and B-CLL patients
Healthy B-CLL % Variation B-CLLrH
EC-AMP 0.79 0.70 y11 0.88
EC-GMP 0.74 0.64 y13 0.86
ATPrADP 1.74 1.36 y22 0.78
GTPrGDP 2.13 1.55 y27 0.73
)ArG 3.25 4.63 q42 1.38
The ratios were calculated from the mean values reported in
Table 1
EC-nucleotide was evaluated according to the formula: 0.5
.  .NDPqNTP r NMPqNDPqNTP .
) P -0.05 with respect to values in healthy subjects.
( )F. Carlucci et al.rBiochimica et Biophysica Acta 1360 1997 203–210 207
Table 3
Enzymes of catabolic pathway in lymphocytes of healthy subjects and B-CLL patients
 .  .Enzymes Healthy ns5 B-CLL ns5 % Variation Healthy B-CLL % Variation
7 7 7 .  .    nmolrhr10 cells nmolrhr10 cells nmolrhr10 nmolrhrmg nmolrhrmg nmolrhrmg
. . . .cells protein protein protein
)A: AMP deaminase 87.48"6.00 41.88"7.62 y52 239"16 197"1 6–18
) )B: ADA 210.60"57.00 67.20"6.60 y68 575"155 316"31 y45
)C: PNP 435.60"106.80 267.00"78.10 y38 1190"291 1258"368 q6
X )D: Ecto-5 -N 210.90"18.10 37.50"7.40 y82
) )E: e-Ns 53.10"7.20 8.60"2.30 y84 145"19 40"11 y72
) )F: c-N-II 86.60"10.20 29.10"7.00 y66 236"27 137"33 y42
7  . XThe activities are expressed in nmolrh per 10 cells and nmolrh per mg protein means"S.E. . Ecto-5 -nucleotidase activity was not
expressed in terms of mg protein.
We could not refer the activity of ecto 5X-nucleotidase in terms of mg protein since this enzyme is evaluated incubating whole cells, the
protein content of which cannot be determined, instead of lysed extracts.
ns number of cases.
) P-0.05 with respect to healthy subjects.
2.8. Determination of proteins
From each subject a sonically-treated lymphocyte
extract was prepared: the protein content was evalu-
w xated according to Bradford 28 , using bovine albu-
min as standard.
2.9. Statistical analysis of data
The data was analyzed by conventional one-way
analysis for variance. Only P values less than 0.05
were considered significant.
3. Results
In a preliminary screening, the data was expressed
in relation to cells. Table 1 shows the purine nu-
cleotide content of 12 healthy subjects and 12
leukemia patients: NAD, AMP and IMP were higher
while di- and tri-phosphates were greatly reduced in
the patients.
The ratios showed the following slight variations:
EC for AMP and EC for GMP decreased by 10%,
ATPrADP and GTPrGDP decreased by 20%. The
ArG ratio increased significantly by 42% in leukemia
patients.
All the activities involved in nucleotide catabolism,
AMP-deaminase, ADA, PNP and the three isoen-
zymes of 5X-nucleotidase were greatly reduced in
lymphocytes from leukemia patients. The same was
true of the enzymes of the salvage pathway, APRT
and HGPRT.
The incorporation of 14C-formate into IMP, total
adenylates and total guanylates was much reduced.
The patterns were different when the data was
expressed per mg of protein. Protein content de-
Table 4
Enzymes of salvage pathway: APRT and HGPRT in lymphocytes of healthy subjects and B-CLL patients
7Enzymes nmolrhr10 cells nmolrhrmg protein
 .  .Healthy ns5 B-CLL ns5 % Variation Healthy B-CLL % Variation
)A: APRT 84.60"24.60 58.20"7.80 y31 231"67 274"36 q18
) )B: HGPRT 93.60"25.80 36.00"9.00 y61 255"70 169"42 y33
) AqB 178.20 94.20 y47 486 443 y9
7  .The activities are expressed in nmolrhr10 cells and nmolrhrmg protein means"S.E. .
) P-0.05 with respect to values in healthy subjects.
ns number of cases.
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Table 5
De novo synthesis in lymphocytes of healthy subjects and B-CLL patients
6Nucleotides pmolr10 cells pmolrmg protein
 .  .Healthy ns3 B-CLL ns3 % Variation Healthy B-CLL % Variation
) )Total adenylates 38"2.1 5 "1.6 y87 1038"57 235"75 y77
) )Total guanylates 6"1.6 2 "0.4 y66 164"43 94"18 y43
) )IMP 5"0.5 1.4"0.2 y72 136"13 66"9 y51
Incorporation of 14C-formate into IMP, total adenine nucleotides and total guanine nucleotides in PBL of healthy subjects and leukemia
6 X  . patients. The results are expressed in pmolr10 cells and pmolrmg protein after 150 of incubation of cell suspension mean"S.E. see
.Section 2 .
) P-0.05 with respect to healthy subjects.
creased from an average of 36.59"3.4 mgr106 cells
in healthy lymphocytes to 21.22"2.27 mgr106 cells
 .in the B-CLL cells means"SE . The increase in
AMP, IMP and NAD was therefore more remarkable.
The decrease in the other nucleotides was no longer
significant with respect to the controls. Total adeny-
lates decreased only by 8%; total guanylates by 35%:
the strong increase in IMP and NAD content in-
volved an increase of total nucleotides. All such data
are comparatively clear in Table 2.
The decrease in specific activity of all the enzymes
of the catabolic pathway was less significant than that
of their absolute values. ADA underwent a marked
reduction. The decrease in AMP-deaminase was not
 .significant y18% , and PNP was substantially un-
changed. Even when the activity was expressed per
mg of protein, the two soluble forms, e-N-s and
c-N-II, were much lower in cells of leukemia patients
 .see again Table 3 . In the case of the salvage
pathway, the specific activity of APRT increased by
about 18%; HGPRT continues to be reduced, by 33%
 .see Table 4 .
A significant decrease in de novo synthesis was
still observed. The incorporation of the radiolabelled
precursor into IMP, total adenylates and total guany-
lates was reduced: the greatest reduction was that of
 .adenine nucleotides see Table 5 .
4. Discussion
Our data demostrates many changes in purine
metabolism in chronic lymphocytic leukemia. All the
changes observed were specific for B-CLL, and are
related to the leukemic character of the cells and not
only to the B type, which is prevalent in these
patients. The main pathways of purine metabolism
are substantially similar in B and T lymphocyte
populations, as demonstred by nucleotide content, the
most representative parameter, which is overlapping
w xin normal B and T cells 29 .
A very interesting point was the discrepancy of the
patterns obtained when the experimental results were
expressed in different ways. The lower values of
nucleotide content, de novo synthesis and enzyme
activities shown by data referred to cells, represent
the absolute situation in relation to normal cells.
Since both the biosynthetic pathway and the
catabolism of nucleotides were reduced, at a first
sight it may seem that the purine nucleotide
metabolism does not meet the needs of the leukemia
cell. However the decrease in nucleotide content is
somehow limited and controlled, since all the ratios
which represent cell energy and viability were only
slightly reduced.
When the data is expressed per mg of protein to
.represent the functional compartment of the cells ,
the variations observed were more selective. Total
adenylate content was not reduced: infact, de novo
synthesis of IMP and of total adenylates decreased
sharply but there was a compensatory even not
.significant increase in APRT. We underline that
most nucleotides of lymphocytes are formed through
w xthe salvage pathway 27 . AMP can also be synthe-
sized through the action of adenosine kinase: Dietz
w xand Czebotar 30 report a higher average activity of
this enzyme in CLL lymphocytes. Combining our
data with those of literature, we conclude that ade-
nine nucleotide formation is substantially not affected
in leukemia cells.
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On the other hand, several differences between
healthy and CLL lymphocytes were evident, whether
the data was expressed per cells or per mg of pro-
teins:
1. the two forms of 5X-nucleotidase activity decreased
sharply;
2. NAD and IMP increased;
3. guanylate synthesis decreased whether evaluated
in terms of the de novo pathway or the activity of
HGPRT;
4. total guanylate content decreased sharply;
5. the ArG ratio increased considerably
The changes in these parameters may play a spe-
cific role in the biology of the cell in CLL and not
only in purine nucleotide metabolism. The formation
of adenosine by 5X-nucleotidase at the cell surface,
the presence of adenosine receptors and the relation-
ship of 5X-nucleotidase deficiency to severe immun-
 . w xodeficiency syndrome SCID are well known 31 . It
is evident that the decrease in enzyme activity is
related to the lower immunological capacity of the
lymphocytes in leukemia patients.
The enhanced NAD levels may be related to the
fact that CLL lymphocytes have higher than normal
 .levels of poly adenosine diphosphate ribose poly-
merase, an enzyme which uses NAD as substrate
w x32 .
The high levels of IMP are more difficult to be
interpreted and may be due to different reasons. First,
it could be linked to reduced channelling at the
inosinic branch point. However, even if the activity
could be assayed only in dialyzed extract, Becher and
w xLohr 33 found similar IMP-dehydrogenase activity¨
in normal and CLL lymphocytes. While the behavior
of AMP deaminase and HGPRT cannot be responsi-
 .ble both are only slightly decreased , the lower
c-N-II activity can partially justifie the accumulation
of IMP. The most likely explanation of the increased
IMP levels lies therefore in an altered regulation of
the different pathways which, through an intricate
mechanism, lead to IMP accumulation de novo syn-
thesis, IMP dehydrogenase, GMP reductase, salvage
pathway, AMP deaminase and feedback inhibition of
.the inosinic branch point .
It is known that unstimulated B-CLL cells repre-
sent an homogeneous population with the same cell
 .cycle position G0 as resting peripheral blood lym-
w xphocytes 34 , therefore differences in protein content
cannot be ascribed to comparison of cells in different
cellular cycle phases. The lower formation of guany-
lates might explain the reduced protein content, due
to a likely decreased protein synthesis, since GTP is
the energy source for the process. Many translation
factors, the G-protein superfamily, bind either GTP
or GDP: as a consequence, alterations in GTP and
GDP cell content would interfere with cell recogni-
tion, which is a crucial immunological property of
lymphocytes.
The low content of guanylates may also explain
the lower formation of nucleic acids at least in circu-
w xlating leukemic lymphocytes. Berger et al. 35 evalu-
w3 xated DNA synthesis incubating, with H de-
oxythymidine, intact peripheral blood lymphocytes
from healthy donors and CLL patients, immediately
after their isolation and on successive days following
 .a treatment with phytohemagglutinin PHA . The rates
of DNA synthesis measured immediately after isola-
tion from blood were low: they were within the same
range for both the normal and CLL cells. After PHA
stimulation, lymphocytes from normal donors showed
their peak DNA synthesis on the 3rd or 4th day after
w3 xstimulation, while the peak of H dThd incorpora-
tion by CLL cells was lower and occured later than
that demonstrated by normal cells.
In our study we found an increase in ArG ratio,
which is inversely related to the production of nucleic
acids and to the proliferative capacity of the cells.
While a definite conclusion cannot be drawn from the
evaluation of the ArG ratio alone, the present experi-
ments indicate that the combined study of purine
nucleotide metabolism and nucleic acids which has
.never been done until now is essential for a better
understanding of the physiopathology of leukemia
cells.
All the changes in activity of the enzymes ob-
served may be linked to alterations in the correspond-
ing genes, which need to be characterized, both in
normal and leukemia cells. It is known that some
 X .purine enzymes 5 -N and ADA play an important
w xrole in lymphocyte function 31 . There is also accu-
mulating evidence that enzymes from purine
metabolism may be biochemical markers of lymphoid
malignancy. Since most cytostatics are purine ana-
logues and generally have to be converted to their
active form by one of the purine interconversion
enzymes, more knowledge of purine metabolism at
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the level of enzyme activity and gene regulation
could contribute to a more specific cancer chemo-
therapy, which might have a preferential target in
guanylate metabolism.
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